- Home
- SOGP vs SLXN Comparison
SOGP vs SLXN Comparison
Compare SOGP & SLXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOGP
- SLXN
- Stock Information
- Founded
- SOGP 2010
- SLXN 2008
- Country
- SOGP Singapore
- SLXN Israel
- Employees
- SOGP N/A
- SLXN N/A
- Industry
- SOGP
- SLXN
- Sector
- SOGP
- SLXN
- Exchange
- SOGP NYSE
- SLXN NYSE
- Market Cap
- SOGP 6.9M
- SLXN 6.9M
- IPO Year
- SOGP 2020
- SLXN N/A
- Fundamental
- Price
- SOGP $1.33
- SLXN $0.95
- Analyst Decision
- SOGP
- SLXN Strong Buy
- Analyst Count
- SOGP 0
- SLXN 1
- Target Price
- SOGP N/A
- SLXN $5.00
- AVG Volume (30 Days)
- SOGP 10.2K
- SLXN 1.2M
- Earning Date
- SOGP 06-17-2025
- SLXN 05-13-2025
- Dividend Yield
- SOGP N/A
- SLXN N/A
- EPS Growth
- SOGP N/A
- SLXN N/A
- EPS
- SOGP N/A
- SLXN N/A
- Revenue
- SOGP $278,363,908.00
- SLXN N/A
- Revenue This Year
- SOGP $48.88
- SLXN N/A
- Revenue Next Year
- SOGP N/A
- SLXN N/A
- P/E Ratio
- SOGP N/A
- SLXN N/A
- Revenue Growth
- SOGP N/A
- SLXN N/A
- 52 Week Low
- SOGP $1.18
- SLXN $0.58
- 52 Week High
- SOGP $2.58
- SLXN $41.85
- Technical
- Relative Strength Index (RSI)
- SOGP 43.20
- SLXN N/A
- Support Level
- SOGP $1.20
- SLXN N/A
- Resistance Level
- SOGP $1.32
- SLXN N/A
- Average True Range (ATR)
- SOGP 0.06
- SLXN 0.00
- MACD
- SOGP 0.04
- SLXN 0.00
- Stochastic Oscillator
- SOGP 85.14
- SLXN 0.00
About SOGP SOUND GROUP INC SPON ADS EA REP 200 ORD SHS(POST SPLIT)
Sound Group Inc is a world-wide audio-centric social and entertainment company. It Leverages broad product portfolio and in-house technologies, Sound Group caters to user interest in audio entertainment and social networking. Sound Group nurtures a globally diverse and inclusive team, drawing on talent from various countries and regions world-wide.
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.